Life Science Accounting Update Conference
Venue: Princeton Wyndham
|Event Date/Time: Nov 10, 2011|
From health care reform implications to collaboration accounting to valuing R&D, this conference will address the latest developments in key areas. You'll hear from experts at Deloitte, Ernst & Young, PwC, KPMG, life science analysts and your industry counterparts.
* Understand the latest accounting changes in key areas
* Recognize the timelines and key factors affecting the life science industry
* Begin to assess the effects of these standards on your company or clients
Register Now Â» Cost $995 Save $100 by booking at least 45 days in advance
Save another $100 by being one of first 25 to register
*Both discounts are still available
You can also register by phone, call (877) 440-0227
or Email us to be invoiced at: email@example.com
Rooms are available at $129/night
Below is the agenda and speaker details from the May San Jose event. The Princeton speakers will be posted by Mid-July.
Agenda: DAY 1
8:00 8:45 Continental Breakfast and Registration
8:45 10:30 Technical Accounting Update
Update on latest relevant developments, amendments and EITFs
Financial Statement Presentation
IFRS Joint Project Focus
10:30 10:45 Break
10:45 12:00 Collaboration Accounting
Revenue recognition issues
12:00 1:00 Lunch
1:00 2:30 Industry Panel: Accounting Issues
Introduction and thumbnail profile
Best practices in applying the onslaught of accounting changes
Obstacles and opportunities
What's on the horizon?
2:30 2:45 Break
2:45 4:00 Tax Issues
Impact of healthcare reform
Tax implications of equity transactions
R&D tax credits
Pitfalls and best practices
4:00 5:30 Revenue Recognition
Resulting changes to sales/operations/IT/accounting policies
Rev Rec for new products
Agenda: DAY 2
8:30 10:30 Regulatory and Legal Update
Financial Regulatory Reform
SEC Enforcement Issues in Life Sciences
SEC Comment Letter Trends
10:30 10:45 Break
10:45 12:00 Valuation Issues
Fair value accounting
Industry standards for valuation models
Valuing R&D Projects
Valuation and impairment of intangible assets
12:00 1:00 Lunch
1:00 2:30 Industry Overview Panel: Perpsective of Dealmakers and Analysts
Industry performance overview and deal trends
IPO Process/investment strategies: tapping into the public markets
Earnings outlook for benchmark companies
2:30 2:45 Break
2:45 4:00 Accounting for Financial Instruments
Speakers: Deloitte Financial Instruments Project overview
Classification, measurement and impairment: FASB vs. IASB
Financial Instruments with characteristics of equity
4:00 4:05 Wrap-Up
Conference speakers include:
Brian Jobe, Deloitte, Partner in Deloitte & Touche LLP's Financial Accounting and Reporting Services practice, and currently leads the practice's efforts related to the Life Sciences industry.
For the past eleven years, Brian has provided accounting policy, transaction structuring, technology, and other consulting services to Fortune 1000 and international companies.
Laura Berezin, Hogan Lovells, Partner with focus on corporate securities and complex corporate finance transactions, with a particular emphasis on representing clients in the life sciences industry.
Laura is listed in The Best Lawyers in America in the categories of Biotechnology Law and Securities Law and recognized in The Legal 500 in the Capital Markets practice area.
Daniel Coleman, Ernst & Young, Partner specializing in life science and high technology industries.
Dan is the author for several Ernst & Young publications on accounting matters relevant to the life science industry. His clients have included Genentech, Intel, Exelixis, DURECT, XOMA, PDL BioPharma, Abgenix, Conor Medsystems, CV Therapeutics, Facet Biotech, Cell Genesys, and Cohesion.
Brian Fields, KPMG, Partner in Department of Professional Practice
Prior to his current role, Brian served as a Professional Accounting Fellow at the SEC, where he focused on oversight of accounting standard setting and interpretation of accounting requirements. Ã‚ Focus areas included the life sciences industry as well as various SEC initiatives related to the financial crisis.
Michael Formolo, Ernst & Young, Senior Manager serving the Life Science Industry.
Michael is qualified in both internal and external financial reporting, and frequently assists companies with emerging company accounting issues, such as stock based compensation and revenue recognition. His clients have included Gilead Sciences, Intuitive Surgical, XOMA, Nektar Therapeutics, Affymax, and ChemoCentryx.
Dante Giannini, PwC, Partner and National Tax Leader for Life Science Industry.
Dan graduated from the Santa Clara University with degrees in Accounting and Law (Magna Cum Laude) and has over 30 years as a lawyer and CPA in Silicon Valley. Clients include life sciences and other technology companies from start-up through large multinational including Novartis, Gilead Sciences, CV Therapeutics, Affymax and Intuitive Surgical. He has advised on over 40 IPO's and 300 acquisition, merger, joint venture and reorganization transactions.
Govind Gupta, Duff & Phelps, Managing Director in the Silicon Valley office and part of the Valuation Advisory Services business unit.
Govind has an exclusive focus on the software, semiconductor and life sciences industries. He has more than 12 years of experience in performing valuations for financial reporting and tax purposes, specializing in the technology and pharmaceutical industries.
Jennifer Jarrett, Citigroup, Managing Director Healthcare Investment Banking.
Jennifer has focused on both large and small cap biotechnology companies throughout her 15 year investment banking career. Prior to Citigroup, Jennifer was Managing Director at Credit Suisse based in San Francisco. She received an MBA from Stanford University and is a graduate of Dartmouth College.
Matthew Pfeffer, Mannkind, Corporate VP and CFO.
Previously Mr. Pfeffer served as CFO of VaxGen Inc. and Cell Genesys. Prior to that Mr. Pfeffer served in a variety of financial management positions at other companies including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse.
Vickie Reed, Amylin Pharmaceuticals, Associate Director of Finance.
Vickie has technical accounting and external reporting responsibilities at Amylin. Prior to her current role, Vickie was Finance and Accounting Director at TorreyPines Therapeutics and Accounting Manager at Genstar Therapeutics. Vickie began her career at Price Waterhouse.
Joseph Olson, PwC, Director specializing in Life Science Industry.
(full bio to come)
John McKenna, Cooley, Partner in the Business department and a member of the Securities Regulation practice group.Ã‚
Mr. McKenna practices corporate and securities law, with an emphasis on the representation of publicly-traded companies and the formation, financing and general representation of emerging growth companies.
Jim Welch, AcelRX Pharmaceuticals, Chief Financial Officer.Ã‚
Prior to joining AcelRX, Mr. Welch was CFO at Cerimon Pharmaceuticals and also served as Chief Financial Officer and Corporate Strategy at Rigel Pharmaceuticals and CFO of Biocircuits Corporation.
Mike Powell, Sofinnova Ventures, General Partner.Ã‚
Mike has more than 25 years of pharmaceutical development experience, and he has focused interest in clinical-stage product companies, particularly in the oncology, endocrine, and neurology areas. He joined Sofinnova Ventures as a General Partner in 1997 as a member of the Life Science investment team. Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including an 1,100Ã¢â‚¬â€œpage treatise on vaccine design.